Company / Current Liabilities
4D Molecular Therapeutics, Inc. Current Liabilities History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$44.0M
FY2025
5-year range
$15.7M / $44.0M
FY2021-FY2025
Trend
+50.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Liabilities has increased for 3 consecutive years, from $16M in FY2022 to $44M in FY2025.
Based on SEC 10-K filings.
$44M in FY2025 with a 5-year CAGR of +21.3%.
Increased from $19M to $44M over the past 2 years.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- +40.9%
- 5-Year CAGR
- +21.3%
- 10-Year CAGR
- -
Key checks
Key Insights
- 4D Molecular Therapeutics, Inc.'s current liabilities has grown for 3 consecutive years.
- 5-year CAGR of +21.3%, indicating consistent growth.
- In FY2025, current liabilities increased 50.9% year-over-year.
- Lowest current liabilities in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.26 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $44.0M | +50.9% |
| FY2024 | $29.1M | +53.8% |
| FY2023 | $19.0M | +20.5% |
| FY2022 | $15.7M | -3.7% |
| FY2021 | $16.3M | -2.4% |
| FY2020 | $16.7M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026